Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 4/20 | 0.40 |
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | DRD2 | P14416 | 5/20 | 0.39 |
| ▸ | DRD1 | P21728 | 4/20 | 0.39 |
| ▸ | DRD4 | P21917 | 4/20 | 0.39 |
| ▸ | DRD5 | P21918 | 4/20 | 0.39 |
| ▸ | DRD3 | P35462 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 3/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.37 |
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21126292 | 0.87 | MAOA (0.38) | TLR9TLR8TLR7MAOAMAOB | |
| SCHEMBL19782459 | 0.86 | MAOA (0.40) | MAOAMAOBDRD2DRD1DRD4 | |
| SCHEMBL25091834 | 0.81 | TLR9 (0.42) | TLR9TLR8TLR7 | |
| SCHEMBL14925539 | 0.79 | RAD52 (0.41) | DRD2DRD1 | |
| SCHEMBL8054291 | 0.77 | MAOA (0.44) | TLR9TLR8TLR7MAOAMAOB | |
| SCHEMBL10513565 | 0.75 | PARP1 (0.43) | MAOAMAOBDRD2DRD1DRD4 | |
| SCHEMBL3308819 | 0.75 | MAOA (0.42) | MAOAMAOBDRD2DRD1DRD4 | |
| SCHEMBL13160139 | 0.73 | PRKDC (0.33) | — | |
| SCHEMBL19398845 | 0.72 | HDAC6 (0.43) | TLR9TLR8TLR7MAOAMAOB | |
| SCHEMBL20645741 | 0.72 | MAOA (0.40) | MAOAMAOBDRD2DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
| US-RE48239-E1 | Heteroaryl pyridone and aza-pyridone compounds | GENETECH, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| WO-2020102096-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200062769-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2020-02-27 | — | — | US | disclosed |
| WO-2018045971-A1 | PYRIDO FIVE-ELEMENT AROMATIC RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海海和药物研究开发有限公司 | 2018-03-15 | — | — | WO | disclosed |
| US-20180071286-A1 | HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS | GENENTECH, INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-9782405-B2 | Heteroaryl pyridone and aza-pyrodine compounds | GENENTECH, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160228432-A1 | HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS | GENENTECH, INC. (US) | 2016-08-11 | — | — | US | disclosed |
| US-9238655-B2 | Heteroaryl pyridone and aza-pyridone compounds | GENENTECH, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-8921353-B2 | Heteroaryl pyridone and aza-pyridone compounds | GENENTECH, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140378432-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH INC (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140194408-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8716274-B2 | Heteroaryl pyridone and aza-pyridone compounds | GENENTECH, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | TLR9 96/4885TLR8 34/4885TLR7 97/4885 |
| US-20160228432-A1 | HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS | TYK2, BTK, PDXK | TLR9 409/4885TLR8 1006/4885TLR7 747/4885 |
| US-20180071286-A1 | HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS | TYK2, BTK, PDXK | TLR9 409/4885TLR8 1006/4885TLR7 747/4885 |
| US-20200062769-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | TLR9 956/4885TLR8 1082/4885TLR7 786/4885 |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | TLR9 956/4885TLR8 1082/4885TLR7 786/4885 |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | BTK, PDXK, TYK2 | TLR9 878/4885TLR8 1507/4885TLR7 531/4885 |
| US-20140378432-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | TLR9 956/4885TLR8 1082/4885TLR7 786/4885 |
| US-20140194408-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | BTK, PDXK, TYK2 | TLR9 878/4885TLR8 1507/4885TLR7 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.